Clene Announces New CNM-Au8® Biomarker and Clinical Efficacy Data Submitted to FDA In Support of Treatment For ALS

Stock Information for Clene Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clene Inc.

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings
Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025
Presenting on Emerging Growth Conference 82 Day 1 on May 21; Register to live stream
Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights
Clene Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference
Presenting on Emerging Growth Conference 81 Day 2 on April 17; Register to live stream
Clene to Present at the Emerging Growth Conference
Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.